Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

We expect Amgen AMGN to beat expectations when it reports fourth-quarter and full-year 2024 results on Feb. 4, after market ...

Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology powerhouse with an excellent track-record on developing and commercialising products targeting four main therapeutic areas: general medicine ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

When talking about growth in the years to come, Amgen has several levers it can pull. For starters, we can look at already approved products with growth potential. Tepezza, which became part of ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while - ...

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

Equities research analysts at William Blair reduced their FY2024 earnings per share estimates for shares of Amgen in a ...